PMOS (formerly known as PCOS), insulin resistance, and GLP-1 medications: what the research does and does not show.

What this page is — and what it is not

This page is an educational guide, not a cure and not a treatment promise. Nothing discussed here treats, cures, or reverses PMOS (formerly known as PCOS) itself — PMOS is a chronic condition managed over time, and no medication on this page changes that.

It is also not a replacement for guideline-established care. Lifestyle change, metformin, combined hormonal contraceptives, spironolactone for hirsutism and acne, and letrozole for ovulation induction when fertility is the goal remain the guideline backbone, and nothing here substitutes for any of them.

What is described here is a set of off-label adjuncts — considered after a formal PMOS diagnosis with other causes excluded, and only after a clinician reviews your labs, cycle history, and pregnancy intentions. If that is where you are starting, this page can help you have that conversation.

Insulin is the engine, and that is where peptides intervene

When cells respond poorly to insulin, the pancreas compensates by producing more of it. That excess insulin does three things inside the ovary and liver that together explain most of PMOS. It acts on ovarian theca cells alongside luteinizing hormone to increase androgen production. It suppresses the liver's output of sex hormone-binding globulin, the protein that keeps testosterone bound and inactive — so less SHBG means more free, biologically active testosterone even when total testosterone barely moves. And it disrupts the orderly maturation of follicles, which is why ovulation becomes irregular or stops.

The loop then feeds itself. Higher androgens promote visceral fat, visceral fat worsens insulin resistance, and insulin climbs further. This is why insulin-sensitizing treatment sits at the center of modern PMOS care rather than at the edges, and why the most useful peptide protocols for PMOS are metabolic rather than reproductive.

GLP-1 receptor agonists — semaglutide, and the dual GLP-1/GIP agonist tirzepatide — improve insulin sensitivity, slow gastric emptying, and reduce hepatic fat and visceral adiposity. In women with PMOS and overweight or obesity, multiple randomized trials and meta-analyses show meaningful reductions in weight and in insulin resistance markers such as HOMA-IR and fasting insulin, and several also show falling total and free testosterone and improved menstrual regularity. Head-to-head analyses against metformin generally favor GLP-1 therapy for weight and find it comparable or better on several metabolic and hormonal endpoints, though the trials are mostly small and run three to six months.

For lean PMOS, or for a woman who has insulin resistance but no real weight to lose, the rationale for microdosing is straightforward: use a dose low enough that appetite and body weight are largely unaffected, high enough to improve insulin sensitivity and lower the compensatory hyperinsulinemia that is driving ovarian androgen output. This is a mechanistic extrapolation and we will say so plainly — no dedicated trial has tested microdosed GLP-1 in lean PMOS for hormonal or reproductive endpoints. It is individualized, off-label, and belongs under supervision.

Glutathione and NAD+ address a different layer. PMOS is consistently associated with elevated oxidative stress, and glutathione is the body's primary intracellular antioxidant — the molecule spent neutralizing reactive species and supporting hepatic detoxification pathways, which matters because fatty liver travels with PMOS more often than most women are told. NAD+ sits in the mitochondria, and PMOS oocytes show mitochondrial dysfunction that appears to contribute to egg and embryo quality. In animal models, including a PMOS model, NAD+ repletion restored oocyte quality — a genuinely interesting finding that has not yet been reproduced in human trials.

Researched benefits

The evidence is real but uneven: multiple randomized trials and meta-analyses support GLP-1 therapy for weight, insulin sensitivity, androgens and cycle regularity in PMOS with overweight or obesity, while tirzepatide-specific PMOS data is earlier — a low-dose tirzepatide plus metformin trial and dedicated trials still recruiting. Microdosing for lean PMOS has no dedicated trials at all and rests on mechanism. Inositol and NAC have modest genuine randomized evidence as adjuncts. NAD+ for oocyte quality and MOTS-c for insulin sensitivity remain preclinical or very early in humans, with no completed human trial of injected MOTS-c in any population. Lifestyle change, metformin, combined oral contraceptives, letrozole for fertility and spironolactone for hirsutism remain the guideline-established backbone, and nothing here replaces them.

How PMOS protocol is dosed

There is no validated PMOS dose, because the dose-finding trials have not been done for this indication. In practice a microdose GLP-1 protocol sits near the bottom of the standard titration ladder — enough to move insulin sensitivity, low enough to avoid nausea and unintended weight loss in a woman who does not need it. Women with significant insulin resistance and obesity may titrate higher toward standard weight-management dosing. Your physician sets the starting dose, whether it advances, and how long the cycle runs.

Tirzepatide and semaglutide are both injected once weekly. Glutathione is typically prescribed as a subcutaneous injection two to three times weekly, often alongside NAC as an oral precursor, because oral glutathione is largely degraded in the gut before it is absorbed. NAD+ protocols are dosed individually and usually cycled.

Inositol is worth mentioning even though we do not compound it: myo-inositol with D-chiro-inositol in roughly a 40 to 1 ratio has randomized evidence for modest improvements in fasting insulin, HOMA-IR and ovulation, costs very little, and has an excellent safety profile. It is not a substitute for metformin or GLP-1 therapy, but it is a reasonable adjunct and your clinician can advise on it.

Everything we prescribe is compounded by our licensed 503(A) pharmacy partner after a physician reviews your intake — including your cycle history, your pregnancy intentions and your contraception.

• Injectable (subcutaneous)

  Semaglutide and tirzepatide are injected once weekly into fatty tissue — abdomen, thigh, or the back of the upper arm — on the same day each week. Glutathione and NAD+ are injected subcutaneously on the schedule your clinician sets. Most clients self-administer at home after brief instruction.

At Origin Wellness, dosing is never self-directed. Your protocol is written by a licensed physician after reviewing your assessment, and it is adjusted at follow-up based on your response. Read more about how that review works on our approach page.

Safety, side effects, and who should avoid it

The single most important thing to understand before starting GLP-1 therapy for PMOS is that it can restore your fertility, sometimes quickly and sometimes unexpectedly. Women who had been told they rarely ovulate, or that conceiving would be difficult, have become pregnant on these medications — often enough that it has become a documented pattern in the literature. That is wonderful news in one sense and a serious risk in another, because GLP-1 medications are not considered safe in pregnancy.

Which means two things. If you do not want to become pregnant, you need reliable contraception the entire time you are on treatment, no matter what you have been told about your fertility in the past. And if you do want to become pregnant, the medication has to be stopped well before you try — labeling for semaglutide recommends discontinuing at least two months before a planned pregnancy given its long half-life, with similar precautions for tirzepatide. Fertility treatment in PMOS has its own established path, and letrozole rather than a peptide is the first-line ovulation induction agent.

Beyond that, the usual GLP-1 profile applies. Nausea, constipation or diarrhea, reflux and reduced appetite are common early and typically ease with slow titration. Less common but important: gallstones and gallbladder disease, rare pancreatitis, and rare reports of bowel motility problems. Combined oral contraceptives can generally be taken alongside GLP-1 therapy, though delayed gastric emptying can theoretically affect absorption of oral medications, so timing or a non-oral contraceptive method is sometimes preferable if GI side effects are significant.

One thing we will not prescribe for PMOS is growth hormone or a GH secretagogue such as sermorelin. There is no evidence base for it in PMOS, and growth hormone can worsen insulin resistance — the opposite of the goal. If another provider has offered you that for PMOS, we would ask them why.

• • Improved insulin sensitivity can restore ovulation — use reliable contraception throughout treatment unless you are actively trying to conceive.
• • GLP-1 medications must be stopped before attempting pregnancy; semaglutide labeling advises at least two months of washout, and tirzepatide carries similar precautions.
• • Not appropriate during pregnancy or breastfeeding.
• • Not appropriate with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome.
• • Disclose any history of pancreatitis, gallstones or significantly elevated triglycerides before starting.
• • Not appropriate with severe gastroparesis or significant GI motility disorders; a history of an eating disorder requires careful evaluation first.
• • PMOS should be formally diagnosed and other causes — thyroid disease, elevated prolactin, non-classic congenital adrenal hyperplasia — excluded before treating.
• • Peptide therapy does not replace endometrial protection. If you go many months without a period, that needs medical attention regardless of what else you are taking.
• • Growth hormone and sermorelin are not appropriate for PMOS and may worsen insulin resistance.

How PMOS protocol fits into a full protocol

This protocol suits women with diagnosed PMOS whose labs or symptoms point to insulin resistance, who want the metabolic driver addressed rather than each symptom managed separately, and who are either not trying to conceive right now or are willing to plan a washout with their physician before they do. It fits both phenotypes: women carrying weight they have been unable to lose, and lean women whose insulin resistance is invisible on the scale.

It is not the right fit if you are actively trying to conceive this cycle, if you are pregnant or breastfeeding, or if your priority is fertility treatment specifically — that belongs with a reproductive endocrinologist using letrozole and established protocols, and we will refer rather than improvise.

Most women on a PMOS protocol here are enrolled in Origin Balance, our women's program, which pairs the prescription with lab monitoring and coaching across a twelve-week arc. That structure exists because insulin resistance responds to what happens between injections — sleep, resistance training, protein intake, stress — and because watching your labs move is what tells us whether the dose is right.

Discuss a protocol with a physician

Choose the protocol that matches your situation and complete your free health assessment. Please include your cycle history and whether you are planning a pregnancy — both change what a physician can safely prescribe.

Frequently asked questions